Leadership

Our proven executive team brings deep, diverse cell therapy experience and is committed to developing safe, effective, and accessible NK cell therapies to patients. Artiva's Board of Directors and Advisors bring years of expertise to help us realize the full potential of NK cell therapies.

Fred Aslan, M.D.
Fred Aslan, M.D.
Chief Executive Officer
View Bio »
Diego Miralles, M.D.
Diego Miralles, M.D.
President and Head of Research and Development
View Bio »
Subhashis Banerjee, M.D.
Subhashis Banerjee, M.D.
Chief Medical Officer
View Bio »
Jennifer Bush
Jennifer Bush
Chief Operating Officer
View Bio »
Christopher Horan
Christopher Horan
Chief Technical Operations Officer
View Bio »
Benjamin Dewees
Benjamin Dewees
SVP, Regulatory Affairs
View Bio »
David Moriarty, Ph.D.
David Moriarty, Ph.D.
SVP, Clinical Operations
View Bio »
Heather Raymon, Ph.D.
Heather Raymon, Ph.D.
SVP, Research & Early Development
View Bio »
Feng Xu
Feng Xu
SVP, Biometrics
View Bio »
Andrew Cronauer
Andrew Cronauer
VP, General Counsel & Corporate Secretary
View Bio »
Sara Mills
Sara Mills
VP, Regulatory Affairs, CMC and AlloNK Program Lead
View Bio »
John O’Neil, CPA
John O’Neil, CPA
VP, Finance
View Bio »
Nicholas Veomett, Ph.D.
Nicholas Veomett, Ph.D.
VP, Corporate Development
View Bio »
Cliff Wallace
Cliff Wallace
VP, Quality
View Bio »
Secret Link